Alcana

Alnylam Pharmaceuticals researchers last month published details on the company’s efforts to improve lipid nanoparticles for RNAi drug delivery.

Just days before they were scheduled to go to trial, Alnylam Pharmaceuticals and Tekmira Pharmaceuticals announced that they have hammered out a settlement to their protracted patent-infringement and technology-misappropriation lawsuits.

Tekmira Pharmaceuticals' CEO this week provided an update on the company's ongoing litigation with partner Alnylam Pharmaceuticals, confirming that a roughly one-year-old technology-misappropriation lawsuit could be resolved before the end of 2012.

Tekmira Pharmaceuticals said this week that it has secured a $3 million loan, extending its cash runway into 2013.

Tekmira Pharmaceuticals this week announced that it has filed a notice of civil claim in the Supreme Court of British Columbia alleging that “certain individuals” from AlCana Technologies wrongly took “thousands of confidential documents” containing Tekmira information and trade

Alnylam charged Tekmira with wrongly using trade secrets to bolster its own drug delivery technology-development efforts and to file a patent application on Alnylam's phase I liver cancer drug.

During a presentation to investors last week, CEO John Maraganore highlighted the company's collaborations with Massachusetts Institute of Technology and AlCana, but notably made no mention of partner Tekmira Pharmaceuticals, which sued Alnylam earlier in the year.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.